soul trial oral semaglutide cardiovascular outcomes 2025 results Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 Novo Nordisk reports SOUL trial

The GLP-1 didnt just shrink me, it let me move again The testosterone gave me back recovery and drive

A nasogastric tube is inserted if ileus develops

A burning or sharp pain during injection (this may indicate you've hit a blood vessel or muscle) Medication leaking out of the injection site Injection site reactions like bruising, swelling or redness that worsen after the injection Shortness of breath call 911 if this occurs The medication isn't having its intended effects, such as reduced appetite

Marre M., Shaw J., Brandle M., Bebakar W.M., Kamaruddin N.A., Strand J., et al

2 3 4 5 6 7 Mounjaro (tirzepatide) KwikPen Summary of Product Characteristics, sections 4.4 and 4.8, MHRA/emc: The incidence of nausea, diarrhoea and vomiting occurred primarily during dose escalation and decreased over time. 2 Ozempic (semaglutide) 0.5 mg Summary of Product Characteristics, section 4.8, MHRA/emc: Nausea occurred in 17% and 19.9% of patients when treated with semaglutide 0.5 mg and 1 mg, respectively Most events were mild to moderate in severity and of short duration

Phase 2 trial data showed that participants who followed a proper escalation schedule consistently reported better tolerance and lower discontinuation rates than the trial aggregate suggests